The question of whether Epstein-Barr nuclear antigen 1 (EBNA1) includes cytotoxic T lymphocyte (CTL) epitopes has generated considerable scientific interest, primarily due to its important implications for the overall biology of Epstein-Barr virus (EBV). Earlier studies have suggested that EBV-associated malignancies that express only EBNA1 escape virus-specific immune surveillance since this antigen is not a target for CTL recognition. In the present report we have used a modified protocol to demonstrate that EBNA1 includes sequences which can be recognized by both polyclonal and clonal CTLs. CD4
recombinant vaccinia encoding each of the EBV nuclear Epstein-Barr virus (EBV) is a member of the human antigens (EBNA) and latent membrane proteins (LMPs), herpesvirus family that maintains a life-long latent assonumerous CTL epitopes were mapped within EBNA2-6 ciation with B lymphocytes and a permissive association and LMP, while no CTL response was detected against with stratified epithelium in the oropharynx (1, 2) . Two EBNA1. types of EBV (1 and 2, also referred to as A and B) are
The question of whether EBNA1 includes CTL epitopes recognized that show DNA sequence divergence within has generated considerable scientific interest, primarily the BAM H1 WYH and E regions of the genome (3, 4) . due to its important implications for the overall biology of There is now convincing evidence that EBV-specific EBV. First, it has been proposed that the EBV-associated memory CD8
/ and CD4 / cytotoxic T lymphocytes (CTL) tumor, Burkitt's lymphoma (BL), escapes virus-specific are responsible for controlling the level of EBV-positive immune surveillance by restricting latent gene expres-B lymphocytes which all healthy, seropositive individuals sion to EBNA1 (11) . This view is reinforced by earlier carry for life following primary infection with the virus (5-studies which showed that BL patients retain detectable 7). Previous studies have defined the relative distribution EBV-specific T cell surveillance, indicating that CTL dysof CTL epitopes within EBV latent proteins recognized function is an unlikely cause of the outgrowth of these by T cells clones from healthy immune individuals ex-EBV-infected tumors in vivo (12). Second, it has recently pressing an array of MHC class I alleles (8) (9) (10) . Using been shown that EBV-infected B cells, expressing EBNA1 and LMP2a only, are capable of maintaining the latent viral infection in vivo (13) . Third, an earlier study carried 1 A part of this work was presented at the CIBA Foundation Symposium on Vaccines against Virally Induced Cancers; March 15-17, 1994. out by Trivedi and colleagues clearly showed that mam- were not rejected by histocompatible mice, whereas ratio of 20:1). These polyclonal CTLs were tested against autologous phytohemagglutinin (PHA) blasts presensitized with an overlapping net of EBNA1 peptides (15-mer overlapping by 10 amino acids) as described earlier (15) .
Polyclonal CTLs from donors LC and DM, stimulated with autologous LCLs, recognized four different peptides from EBNA1. CTLs from donor LC showed reactivity against peptide 49 (RRGTALAIPQCRLTP), while CTLs from donor DM recognized autologous PHA blasts in the presence of peptides 30 (EPDVPPGAIEQGPAD), 47 (GGSKTSLYNLRRGTA), and 48 (SLYNLRRGTALAIPQ) (Figs. 1a and 1b) . In contrast, CTLs from donors CM and NB showed no significant reactivity against any of the EBNA1 peptides (data not shown). These experiments were repeated with two different blood samples and consistently the same set of peptides was recognized by CTLs from donors DM and LC.
To confirm the data obtained with polyclonal effectors, CTL clones were generated (16) from donors DM and LC by seeding UM cells or purified CD4
/ T cells, after stimulation with either autologous LCLs or EBNA1 peptides (peptides 30, 47, and 48 for donor DM and peptide 49 for donor LC). CD4
/ T cells were purified from fresh UM cells using a Lymphokwik reagent (One Lambda Inc., CA). Colonies were harvested after 3 days and amplified in culture with biweekly restimulation with rIL-2 and autologous LCL precoated with EBNA1 peptide(s). Two CTL clones were isolated from donor DM (referred to as DM2 and DM6) following stimulation with peptide 48 (SLYNLR- it is plausible that some virus-infected B cells maintain a nonimmunogenic phenotype by down-regulating the critical latent proteins needed for CTL recognition. The present study was specifically designed to consider the possibility of detecting an EBNA1-specific CTL response in healthy EBV-seropositive individuals, since earlier studies have essentially drawn their conclusions on the basis of negative evidence. Unfractionated mononuclear (UM) cells (10 6 /ml) from EBV-seropositive donors LC (HLA A1, B8, B18, DR3, DR11), NB (A2, A24, B7, B35, DR11), CM (HLA A11, A24, B7, B44, DR1, DR4), and DM (A24, A29, B44, Bw47, DR1, DR7) were cultivated with irradiated (8000 R) autologous lymphoblastoid cell lines (LCLs) transformed with the and SLYNLRRGTALAIPQ, suggesting that both these were synthesized and screened for recognition by DM2.
As shown in Fig. 3 , 10 different peptides were tested and overlapping sequences might include an EBNA1 epitope. No CTL clones specific for EBNA1 peptides were isocompared for the concentration required for half-maximal lysis of autologous anti-CD40 B cell blasts. These B cell lated from donors LC or DM following stimulation with peptides 30 and 49. blasts were generated as described previously (18) . Based on this analysis, peptide TSLYNLRRGTALA was Characterization (by FACS analysis) revealed that DM2 and DM6 were ú99.0% CD3 / , CD4 / cells, a phenotype the minimal peptide with maximal activity, inducing halfmaximal lysis at a concentration of 0.069 mg/ml. suggesting that these clones might be MHC class IIrestricted. To examine this possibility, autologous PHA An important aspect of the characterization of the CTL clone was to determine whether DM2 could recognize blasts were presensitized with peptide 48 and then exposed to the CTL clones in the presence of anti-class I autologous LCLs transformed with a range of virus strains. These LCLs were established either spontane-(W6/32) or anti-class II (L243) antibody. As shown in Fig.  2 , recognition of peptide 48-coated PHA blasts was ously (19) or by exogenous virus transformation of peripheral B cells using type 1 or 2 EBV isolates (16) . Surprisblocked by L243 but was not significantly affected by W6/32 antibody. This result confirmed that these CTL ingly, no LCLs were recognized by DM2 (Fig. 4) . The lack of CTL recognition by DM2 was not due to any defect in clones are MHC class II-restricted.
To minimalize this CTL epitope, overlapping peptides the expression of MHC class II alleles, since all LCLs were efficiently recognized by the clone if presensitized Indeed, the sequence conforms to the previously pubwith the TSLYNLRRGTALA peptide. This result suggests lished HLA DR1 binding motif (20) . that LCLs are unable to process and present the EBNA1
To determine whether the lack of CTL lysis of autolo-CTL epitope endogenously.
gous LCLs by CTL clone DM2 was due to insufficient To define the HLA restriction of the CTL clone DM2, levels of EBNA1 expressed in these cells, DM/B95.8 a panel of allogeneic LCLs, some sharing an MHC class LCLs and DM CD40 B cell blasts were infected with II allele with donor DM, was presensitized with TSLYNLrecombinant vaccinia constructs encoding the full-length RRGTALA and tested in a standard 51 Cr-release assay.
EBNA1 gene (Vacc.EBNA1) and vaccinia encoding T7 As shown in Fig. 5 , peptide-sensitized LCLs from RNA polymerase (Vacc.T7) (8) . Despite high levels of DR1/ve donors, but not DR10ve donors, were recog-EBNA1 expression in these cells as determined by immunized by CTL clone DM2. These results suggest that noblotting (data not shown), no lysis was seen in the peptide TSLYNLRRGTALA is restricted through HLA DR1.
presence of CTL clone DM2 (Fig. 6 ). These results confirm that, although EBNA1 includes a CTL epitope, this epitope is not processed and presented endogenously by EBV-infected cells. Levitskaya and colleagues have recently demonstrated that repeat sequences of glycine-alanine within EBNA1 can inhibit presentation of class I epitopes (21). To explore the possibility that the lack of endogenous processing of the TSLYNLRRGTALA epitope relates to the presence of these repeat sequences, DM target cells were infected with two recombinant vaccinia vectors (Vacc.E1DGA and E1DCGA). Each of these constructs encodes a truncated EBNA1 protein without the glycinealanine repeats but including this epitope (P. M. Steigewald-Mullen and M. G. Kurilla, submitted for publication). Interestingly, target cells expressing these proteins were cleus, thus limiting class II presentation. However, this seems unlikely since target cells were also not recog
